Global Information
회사소개 | 문의

세계의 피부과 시장 예측(-2028년)

The Global Dermatology Market to 2028

리서치사 GMR Data Ltd
발행일 2018년 06월 상품 코드 384190
페이지 정보 영문 180 Pages
가격
US $ 2,501 ₩ 2,823,100 PDF by E-mail (Single User License)
US $ 4,501 ₩ 5,080,700 PDF by E-mail (Site License)
US $ 11,201 ₩ 12,643,600 PDF by E-mail (Global License)


세계의 피부과 시장 예측(-2028년) The Global Dermatology Market to 2028
발행일: 2018년 06월 페이지 정보 : 영문 180 Pages

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

한글목차

세계의 피부질환 치료제(처방약) 시장은 2017년에 384억 달러를 기록했습니다. 이 시장은 2018년에 441억 달러에 달할 것으로 예측됩니다.

세계의 피부질환 치료제 시장에 대해 조사분석했으며, 피부질환 세분화, 현재 치료법, 신약 연구개발 동향, 시장 규모 추이와 예측, 주요 기업 개요, 전문가 견해 등을 정리하여 전해드립니다.

제1장 개요

제2장 세계 피부과 시장의 현재 동향·발전

  • 현재 동향, 과제 및 발전
  • 피부과의 생물제제
  • M&A

제3장 세계의 피부과 치료제 시장·예측

  • 세계 시장의 개요
  • 세계의 피부과 치료제 시장 : 종류별

제4장 세계의 심상성좌창(여드름) 처방약 시장·예측

  • 종류와 증상
  • 발증률과 유병률
  • 주요 동향
  • 현재 처방 치료
  • 시장 규모와 예측
  • 출시 치료제 시장과 예측
  • 제III상 파이프라인 예측
  • 제II상 파이프라인 예측
  • 경쟁 분석

제5장 세계의 건선 처방약 시장·예측

  • 종류와 증상
  • 발증률과 유병률
  • 주요 동향
  • 현재 처방 치료
  • 시장 규모와 예측
  • 출시 치료제 시장과 예측
  • 제III상 파이프라인 예측
  • 제II상 파이프라인 예측
  • 경쟁 분석

제6장 세계의 탈모증 처방약 시장·예측

  • 종류와 증상
  • 발증률과 유병률
  • 주요 동향
  • 현재 처방 치료
  • 시장 규모와 예측
  • 출시 치료제 시장과 예측
  • 제III상 파이프라인 예측
  • 제II상 파이프라인 예측
  • 경쟁 분석

제7장 세계의 피부암 처방약 시장·예측

  • 종류와 증상
  • 발증률과 유병률
  • 주요 동향
  • 현재 처방 치료
  • 시장 규모와 예측
  • 출시 치료제 시장과 예측
  • 제III상 파이프라인 예측
  • 제II상 파이프라인 예측
  • 경쟁 분석

제8장 세계의 피부 감염증 처방약 시장·예측

  • 종류와 증상
  • 발증률과 유병률
  • 주요 동향
  • 현재 처방 치료
  • 시장 규모와 예측
  • 출시 치료제 시장과 예측
  • 제III상 파이프라인 예측
  • 제II상 파이프라인 예측
  • 경쟁 분석

제9장 세계의 아토피 피부염 처방약 시장·예측

  • 종류와 증상
  • 발증률과 유병률
  • 주요 동향
  • 현재 처방 치료
  • 시장 규모와 예측
  • 출시 치료제 시장과 예측
  • 제III상 파이프라인 예측
  • 제II상 파이프라인 예측
  • 경쟁 분석

제10장 세계의 주사 처방약 시장·예측

  • 종류와 증상
  • 발증률과 유병률
  • 주요 동향
  • 현재 처방 치료
  • 시장 규모와 예측
  • 출시 치료제 시장과 예측
  • 경쟁 분석

제11장 세계 피부과 부문의 주요 국가 시장

  • 미국의 피부과 치료제 시장·예측
  • 영국의 피부과 치료제 시장·예측
  • 프랑스의 피부과 치료제 시장·예측
  • 독일의 피부과 치료제 시장·예측
  • 스페인의 피부과 치료제 시장·예측
  • 이탈리아의 피부과 치료제 시장·예측
  • 일본의 피부과 치료제 시장·예측
  • 기타 지역의 피부과 치료제 시장·예측

제12장 전문가 견해

부록

KSA 18.06.11

영문목차

The global dermatological (prescription) drugs market was valued at $38.4bn in 2017, GMR Data forecast that this will rise to $44.1bn across 2018.

The third in a series of biennial Dermatology reports sees GMR Data again interview industry experts to produce a market leading report that dissects and investigates the key questions in the Global Dermatology Market across the next decade.

GMR Data forecasts that the global dermatology (prescription) drugs market will report a CAGR of 6.4% across 2018 and 2028.

Of the seven dermatological drugs types / segments highlighted in the report, Atopic Dermatitis and Skin Cancer are estimated to display the highest growth rates (10-year CAGR) of 12.8% and 9.2% respectively.

GMR Data attributes this growth to a change in treatment modalities of the mentioned dermatological diseases. The new treatment modality widely uses a targeted approach of 'biological' drugs that are specific, highly efficacious and result in high QALY; for instance - MoAbs or monoclonal antibodies witnessed higher adoption rates in Atopic Dermatitis.

5 Reasons why you must read this report today:

  • 1. Dermatology drug manufacturers are enjoying higher revenues than ever before in this niche market and with increasing prevalence of skin diseases, this will continue across the next decade.
  • 2. A number of leading drugs are set to come off of patent across the forecast period.
  • 3. Pipeline products addressing areas of unmet clinical need, especially in the acne, skin infections and skin cancer markets with the potential to become blockbusters, will launch during the forecast period.
  • 4. Understanding the areas of the market in which growth will occur allows for a more tailored approach to expansion, increasing the chances of success.
  • 5. GMR Data's report gives an in depth and independent view of the leading companies in the dermatology drugs market, ensuring you have all the information needed when moving forward.

Included in the report is analysis of the leading companies and geographies in the dermatology drugs market, as well as of the opportunities and threats facing manufacturers. The report has forecasts for all key submarkets in the market as well as for the leading drugs.

The primary companies in the market are studied with pipeline products and merger & acquisitions in relation to the dermatology sector.

This independent, 180 page report guarantees you will remain better informed than your competition. With over 150 tables and figures examining the dermatology drugs market, the report gives you a visual, one-stop breakdown of the leading products, submarkets and market leaders market revenue forecasts as well as analysis to 2028, which keeps your knowledge that one step ahead, helping you to succeed. This report is essential reading for you or anyone in the pharmaceutical or health care sectors. Purchasing this report today will help you to recognise those important market opportunities and understand the possibilities there.

Table of Contents

1 - Executive Summary

  • 1.1 Executive Summary
  • 1.2 Report Description
  • 1.3 Market Segmentation
  • 1.4 Research Methodology

2 - Current Trends & Developments in the Global Dermatology Market

  • 2.1 Current Trends, Challenges & Developments
    • 2.1.1. Historic Limited Economic Potential - Changed with Introduction of Biologics
    • 2.1.2. Stringent Regulatory Norms for Clearance
    • 2.1.3. Switch from Prescription to OTC
    • 2.1.4. Difficulty with Combination Drugs
  • 2.2 Biologics in Dermatology
  • 2.3 Mergers and Acquisitions

3 - Global Dermatological Drugs Market & Forecast, 2018 - 2028

  • 3.1 Global Market Overview
  • 3.2 Global Dermatological Drugs Market by Type

4 - Global Acne Vulgaris Prescription Drugs Market & Forecast, 2018 - 2028

  • 4.1 Types and Symptoms of Acne Vulgaris
  • 4.2 Incidence and Prevalence of Acne Vulgaris
  • 4.3 Key Trends in the Global Acne Vulgaris Market
  • 4.4 Current Prescription (rx) Treatments for Acne Vulgaris
  • 4.5 Global Acne Vulgaris Market Size &Forecast, 2018 - 2028
  • 4.6 Current Marketed Drugs & Forecast
    • 4.6.1. Solodyn Market and Forecast
    • 4.6.2. Doryx Market and Forecast
    • 4.6.3. Epiduo Market and Forecast
  • 4.7 Acne Vulgaris - Phase III Drugs Pipeline Forecast
    • 4.7.1. Onexton (Valeant)
    • 4.7.2. Epiduo Forte (Galderma)
    • 4.7.3. Sarecycline (Actavis)
  • 4.8 Acne Vulgaris - Phase II Drugs Pipeline Forecast
    • 4.8.1. DRM01 (Dermira)
    • 4.8.2. FMX101 (Foamix)
    • 4.8.3. SB204 (Novan Therapeutics)
    • 4.8.4. SEB002 (Sebacia)
    • 4.8.5. MTC896 (Mimetica)
  • 4.9 Competitive Analysis in the Acne Vulgaris Market
    • 4.9.1. Valeant Pharmaceuticals
    • 4.9.2. Dermira
    • 4.9.3. Paratek Pharmaceuticals
    • 4.9.4. Mayne Pharma

5 - Global Psoriasis Prescription Drugs Market & Forecast, 2018 - 2028

  • 5.1 Types & Symptoms of Psoriasis
  • 5.2 Incidence & Prevalence of Psoriasis
  • 5.3 Key Trends in the Global Psoriasis Market
  • 5.4 Current Prescription (Rx) Treatments for Psoriasis
  • 5.5 Global Psoriasis Market Size & Forecast, 2018 - 2028
  • 5.6 Current Marketed Drugs & Forecast
    • 5.6.1. Stelara (Psoriasis) Market and Forecast
    • 5.6.2. Enbrel (Psoriasis) Market and Forecast
    • 5.6.3. Humira (Psoriasis) Market and Forecast
    • 5.6.4. Otezla (Psoriasis) Market and Forecast
    • 5.6.5. Cosentyx (Psoriasis) Market and Forecast
    • 5.6.6. Taltz (Psoriasis) Market and Forecast
    • 5.6.7. Piclidenoson (Psoriasis) Market and Forecast
  • 5.7 Psoriasis - Phase III Drugs (Injectable Biologics) Pipeline Forecast
    • 5.7.1. BI 655066 (Boehringer Ingelheim)
    • 5.7.2. Guselkumab (Janssen)
    • 5.7.3. Tildrakizumab (Sun Pharma)
  • 5.8 Psoriasis - Phase III Drugs (Injectable Biologics) Pipeline Forecast
    • 5.8.1. Cimzia (UBC)
    • 5.8.2. Brodalumab (Astra-Zeneca/Valeant)
  • 5.9 Psoriasis - Phase II Drugs (Injectable Biologics) Pipeline Forecast
    • 5.9.1. Tregalizumab (Biotest AG)
    • 5.9.2. Namilumab (Takeda Pharmaceuticals)
    • 5.9.3. IMO-8400 (Idera Pharmaceuticals)
  • 5.10 Psoriasis - Phase II (10) Drugs (Orally Administered) Pipeline Forecast
  • 5.11 Competitive Analysis In Psoriasis Market
    • 5.11.1. Celgene Corporation
    • 5.11.2. Novartis
    • 5.11.3. Can-Fite BioPharma

6 - Global Alopecia Prescription Drugs Market & Forecast, 2018 - 2028

  • 6.1 Types and Symptoms of Alopecia
  • 6.2 Incidence and Prevalence Of Alopecia
  • 6.3 Key Trends in The Global Alopecia Market
  • 6.4 Current Prescription (Rx) Treatments for Alopecia
  • 6.5 Global Alopecia Market Size And Forecast, 2018 - 2028
  • 6.6 Current Marketed Drugs and Forecast
    • 6.6.1. Propecia Market and Forecast
  • 6.7 Alopecia - Phase III Drugs Pipeline Forecast
    • 6.7.1. Bimatoprost (Allergan)
    • 6.7.2. SM04554 (Samumed)
  • 6.8 alopecia - phase II (2) Drugs Pipeline Forecast
  • 6.9 Competitive Analysis In Alopecia Market
    • 6.9.1. Merck
    • 6.9.2. Samumed
    • 6.9.3. Concert Pharmaceuticals

7 - Global Skin Cancer Prescription Drugs Market & Forecast, 2018 - 2028

  • 7.1 Types and Symptoms of Skin Cancer
  • 7.2 Incidence and Prevalence of Skin Cancer
  • 7.3 Key Trends in the Global Skin Cancer Market
  • 7.4 Current Prescription (Rx) Treatments for Skin Cancer
  • 7.5 Global Skin Cancer Market Size and Forecast, 2018 - 2028
  • 7.6 Current Marketed Drugs and Forecast
    • 7.6.1. Yervoy Market and Forecast
    • 7.6.2. Zelboraf + Cotellic Market and Forecast
    • 7.6.3. Tafinlar + Mekinist Market and Forecast
    • 7.6.4. Keytruda Market and Forecast
    • 7.6.5. Opdivo, Opdivo + Yervoy Market and Forecast
    • 7.6.6. Imlygic Market and Forecast
    • 7.6.7. Erivedge Market and Forecast
    • 7.6.8. Odomzo Market and Forecast
  • 7.7 Skin Cancer - Phase III (12) Drugs Pipeline Forecast
  • 7.8 Skin Cancer - Phase II (53) Drugs Pipeline Forecast
  • 7.9 Competitive Analysis In Skin Cancer Market
    • 7.9.1. Roche Holding (Roche)
    • 7.9.2. Sun Pharmaceutical Industries

8 - Global Skin Infections Prescription Drugs Market & Forecast, 2018 - 2028

  • 8.1 Types and Symptoms of Skin Infections
  • 8.2 Incidence and Prevalence of Skin Infections
  • 8.3 Key Trends in the Global Skin Infections Market
  • 8.4 Current Prescription (Rx) Treatments for Skin Infections
  • 8.5 Global Skin Infections Market Size and Forecast, 2018 - 2028
  • 8.6 Current Marketed Drugs and Forecast - cSSSIS
    • 8.6.1. Cubicin Market and Forecast
    • 8.6.2. Zyvox Market and Forecast
    • 8.6.3. Sivextro Market and Forecast
    • 8.6.4. Orbactiv Market and Forecast
    • 8.6.5. Dalvance Market and Forecast
    • 8.6.6. Tygacil Market and Forecast
    • 8.6.7. Teflaro Market and Forecast
  • 8.7 Current Marketed Drugs and Forecast - Onychomycosis
    • 8.7.1. Kerydin Market and Forecast
    • 8.7.2. Jublia Market and Forecast
  • 8.8 Skin Infections - Phase III (11) Drugs (cSSSIS) Pipeline Forecast
  • 8.9 Skin Infections - Phase III (3) Drugs (Onychomycosis) Pipeline Forecast
  • 8.10 Skin Infections - Phase Ii (3) Drugs (Onychomycosis) Pipeline Forecast
  • 8.11 Competitive Analysis in the Skin Infections Market
    • 8.11.1. Novan Therapeutics

9 - Global Atopic Dermatitis Prescription Drugs Market & Forecast, 2018 - 2028

  • 9.1 Types and Symptoms of Dermatitis
  • 9.2 Incidence and Prevalence of Atopic Dermatitis
  • 9.3 Key Trends in the Dermatitis Market
  • 9.4 Current Prescription (Rx) Treatments for Dermatitis
  • 9.5 Global Atopic Dermatitis Market Size and Forecast, 2018 - 2028
  • 9.6 Current Marketed Drugs and Forecast
    • 9.6.1. Dupixent Market and Forecast
    • 9.6.2. Eucrisa Market and Forecast
  • 9.7 Atopic Dermatitis - Phase III Drugs Pipeline Forecast
    • 9.7.1. ZPL-389 (Ziarco Pharma)
    • 9.7.2. Nanocyclo (Immune Pharmaceuticals)
  • 9.8 Atopic Dermatitis - Phase II Drugs (Orally/Topically Administered) Pipeline Forecast
    • 9.8.1. Tofactinib/Xeljanz (Pfizer)
    • 9.8.2. ZPL-521 (Ziarco Pharma)
    • 9.8.3. OPA-15406 (Otsuka/Medimetriks)
    • 9.8.4. Upadacitinib (AbbVie)
    • 9.8.5. Baricitinib (Eli Lilly/Incyte)
  • 9.9 Atopic Dermatitis - Phase II Drugs (Injectable Moabs) Pipeline Forecast
    • 9.9.1. Bertilimumab (Immune Pharmaceuticals)
    • 9.9.2. Tralokinumab (Leo Pharma/Astra-Zeneca)
    • 9.9.3. Nemolizumab (Chugai Pharmaceuticals)
    • 9.9.4. Lebrikizumab (Roche/Genentech)
  • 9.10 Competitive Analysis in the Atopic Dermatitis Market
    • 9.10.1. Sanofi
    • 9.10.2. Pfizer
    • 9.10.3. Immune Pharmaceuticals

10 - Global Rosacea Prescription Drugs Market & Forecast, 2018 - 2028

  • 10.1 Types and Symptoms of Rosacea
  • 10.2 Incidence and Prevalence of Rosacea
  • 10.3 Key Trends in the Global Rosacea Market
  • 10.4 Current Prescription (Rx) Treatments for Rosacea
  • 10.5 Global Rosacea Market Size and Forecast, 2018 - 2028
  • 10.6 Current Marketed Drugs and Forecast
    • 10.6.1. Finacea Gel + Finacea Foam (Bayer/Foamix)
    • 10.6.2. Mirvaso (Galderma)
    • 10.6.3. Soolantra (Galderma)
    • 10.6.4. Oracea (Galderma)
    • 10.6.5. Rhofade (Allergan)
  • 10.7 Competitive Analysis in Rosacea Market
    • 10.7.1. Bayer
    • 10.7.2. Galderma (Nestle Skin Health)
    • 10.7.3. Allergan

11 - Key National Markets in the Global Dermatology Sector, 2018 - 2028

  • 11.1 U.S Dermatological Drugs Market and Forecast, 2018 - 2028
  • 11.2 U.K. Dermatological Drugs Market and Forecast, 2018 - 2028
  • 11.3 France Dermatological Drugs Market and Forecast, 2018 - 2028
  • 11.4 Germany Dermatological Drugs Market and Forecast, 2018 - 2028
  • 11.5 Spain Dermatological Drugs Market and Forecast, 2018 - 2028
  • 11.6 Italy Dermatological Drugs Market and Forecast, 2018 - 2028
  • 11.7 Japan Dermatological Drugs Market and Forecast, 2018 - 2028
  • 11.8 Row Dermatological Drugs Market and Forecast, 2018 - 2028
    • 11.8.1. Brazil Dermatological Drugs Market and Forecast, 2018 - 2028
    • 11.8.2. Russia Dermatological Drugs Market and Forecast, 2018 - 2028
    • 11.8.3. India Dermatological Drugs Market and Forecast, 2018 - 2028
    • 11.8.4. China Dermatological Drugs Market and Forecast, 2018 - 2028

12 - Expert Opinion

  • 12.1 Galderma
  • 12.2 Ranbaxy

Appendix: Skin Cancer - Phase III & Phase II Drugs Pipeline

Back to Top
아시아 최대 시장정보 제공
전세계에서 발행되고 있는 모든 시장조사보고서를
다루고 있습니다.
사이트에서 검색되지 않는 보고서도 문의 바랍니다.
 
BCC Research